Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
暂无分享,去创建一个
Thomas J. Hardcastle | David Huntsman | Nataliya Melnyk | D. Huntsman | J. Brenton | N. Melnyk | S. Cooke | S. Langdon | J. Temple | C. Ng | M. J. García | Simon Langdon | James D Brenton | Jillian Temple | Susanna L Cooke | Charlotte KY Ng | Maria J Garcia | Tom Hardcastle | M. García | Nataliya Melnyk | Jillian Temple
[1] T. Herzog,et al. Ovarian cancer: a focus on management of recurrent disease , 2006, Nature Clinical Practice Oncology.
[2] D. Huntsman,et al. Critical molecular abnormalities in high-grade serous carcinoma of the ovary , 2008, Expert Reviews in Molecular Medicine.
[3] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[4] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[5] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[6] D J Porteous,et al. WWOX: A candidate tumor suppressor gene involved in multiple tumor types , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. McClatchey,et al. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact , 2007, British Journal of Cancer.
[8] Robert C. Bast,et al. The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.
[9] Noam Harpaz,et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. , 2005, Gastroenterology.
[10] T. Herzog. Recurrent Ovarian Cancer , 2004, Clinical Cancer Research.
[11] D J Ruiter,et al. HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS , 1996, The Journal of pathology.
[12] Thomas J. Hardcastle,et al. Chromosomal instability determines taxane response , 2009, Proceedings of the National Academy of Sciences.
[13] P. Edwards,et al. Distribution of breakpoints on chromosome 18 in breast, colorectal, and pancreatic carcinoma cell lines. , 2006, Cancer genetics and cytogenetics.
[14] S. Kitano,et al. Identification and Cloning of Human G-Protein γ 7, Down-regulated in Pancreatic Cancer , 1998 .
[15] N. Kley,et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. , 1993, Cell.
[16] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[17] Monique Albert,et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. , 2002, Cancer research.
[18] C. Cordon-Cardo,et al. A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.
[19] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[20] W. Hofmann,et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. , 2003, Blood.
[21] M. Toyoda,et al. jumonji downregulates cardiac cell proliferation by repressing cyclin D1 expression. , 2003, Developmental cell.
[22] Joshy George,et al. Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.
[23] James R. Downing,et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.
[24] J. McAlpine,et al. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. , 2008, Gynecologic oncology.
[25] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[26] R. Weichselbaum,et al. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.
[27] L. Foroni,et al. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia , 1999, British Journal of Cancer.
[28] J. Andersen,et al. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases , 2007, Breast Cancer Research and Treatment.
[29] B. Karlan,et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.
[30] C. Maley,et al. Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .
[31] C. Caldas,et al. The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel , 2007, Cancer cell.
[32] S. Rubin,et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Schäffer,et al. Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability. , 2002, Neoplasia.
[34] I. Jacobs,et al. Genetic intra‐tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours , 2007, The Journal of pathology.
[35] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[36] J. Brenton,et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. , 2007, Cancer cell.
[37] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[38] A. Mes-Masson,et al. Characterization of three new serous epithelial ovarian cancer cell lines , 2008, BMC Cancer.
[39] Jun Luo,et al. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.
[40] S. Kitano,et al. Identification and cloning of human G-protein gamma 7, down-regulated in pancreatic cancer. , 1998, Biochemical and biophysical research communications.
[41] J. Smyth,et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. , 1988, Cancer research.
[42] F. Couch,et al. Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma , 2022 .
[43] J. Haines,et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor , 1993, Cell.